Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor "What This Means" Segment | 1 | GlobeNewswire (USA) | ||
16.10. | HCW Biologics Inc.: HCW Biologics to Participate in the 2025 Maxim Growth Summit | 1 | GlobeNewswire (USA) | ||
16.10. | HCW Biologics Inc.: HCW Biologics' Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer | 1 | GlobeNewswire (USA) | ||
16.10. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
30.09. | HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor "What This Means" Segment About its Proprietary T-Cell Engager Program | 1 | GlobeNewswire (USA) | ||
18.09. | HCW Biologics Inc.: HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing | 1 | GlobeNewswire (USA) | ||
16.09. | HCW Biologics Inc.: HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development | 252 | GlobeNewswire (Europe) | Lead product candidate will be advanced to late IND-enabling studies to prepare for clinical trials for evaluation in the treatment of solid tumors Discovery of unique combination of cytokines in... ► Artikel lesen | |
HCW BIOLOGICS Aktie jetzt für 0€ handeln | |||||
12.09. | Why Is HCW Biologics Stock Surging 102% Overnight? | 3 | Benzinga.com | ||
09.09. | HCW Biologics Inc.: HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program | 245 | GlobeNewswire (Europe) | HCW Biologics conducted investigative study to show safe dose levels of its lead drug candidate in non-human primates that were well tolerated at a level significantly higher than the identified efficacious... ► Artikel lesen | |
05.09. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
25.08. | HCW Biologics' Shares Surge After Unveiling Next-Gen Cancer Immunotherapy Platform | 1 | Benzinga.com | ||
25.08. | HCW Biologics meldet vielversprechende Ergebnisse für neue Krebs-Immuntherapie | 15 | Investing.com Deutsch | ||
25.08. | HCW Biologics stock soars on novel cancer immunotherapy breakthrough | 1 | Investing.com | ||
25.08. | HCW Biologics reports promising results for new cancer immunotherapy | 1 | Investing.com | ||
25.08. | HCW Biologics Inc.: HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market | 3 | GlobeNewswire (USA) | ||
19.08. | HCW Biologics erhält Delisting-Mitteilung von der NASDAQ und plant Anhörung | 3 | Investing.com Deutsch | ||
19.08. | HCW Biologics GAAP EPS of -$16.16, revenue of $180.4M | 1 | Seeking Alpha | ||
19.08. | HCW Biologics GAAP EPS of -$16.16 | 1 | Seeking Alpha | ||
18.08. | HCW Biologics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
18.08. | HCW Biologics Inc.: HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results | 789 | GlobeNewswire (Europe) | MIRAMAR, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 42,270 | +0,49 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
VENTYX BIOSCIENCES | 7,440 | +92,75 % | Ventyx Biosciences: NBC feiert Daten-Knall und +928% in 6 Monaten | Der Party-Herbst reißt nicht ab: Nach dem Tenbagger Minerva explodieren im No Brainer Club die nächsten Kurs-Granaten. Eine davon ist die Aktie von Ventyx Biosciences. Die Ventyx-Aktie hatte der No... ► Artikel lesen | |
TANGO THERAPEUTICS | 7,730 | -10,74 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces $225 Million Financing | BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
EVOTEC | 6,866 | +2,08 % | Übernahme von Vidac Pharma und Evotec? 400 Mrd. USD bei Pfizer, Merck und Co im Feuer! | Alarm bei Big Pharma! Donald Trump scheint bei der Reduzierung von Medikamentenpreisen ernst zu machen. Gleichzeitig laufen Patente bei Blockbustern aus und ein 400 Mrd. USD Umsatzausfall droht. Pfizer... ► Artikel lesen | |
HARMONY BIOSCIENCES | 29,335 | +11,75 % | Harmony Biosciences reports Q3 revenue of $239M, raises FY25 revenue guidance | ||
BIONTECH | 90,55 | -1,20 % | Wer im Kampf gegen Krebs auf jeden Fall verdient: NetraMark, Moderna, BioNTech | Zwei Biotech-Pioniere, Moderna und BioNTech, stehen nach ihrem COVID-19-Impfstoff-Erfolg erneut im Rampenlicht - diesmal in einem Wettrennen um innovative Krebstherapien. Beide Unternehmen setzen auf... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,690 | -0,96 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
JANUX THERAPEUTICS | 25,480 | -3,23 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 47,320 | +0,98 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 | SAN DIEGO, Oct. 13, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 18,850 | -1,52 % | Summit Therapeutics: Daten überzeugen - BioNTech beobachten! | Am morgigen Dienstag neigt sich die Jahrestagung der European Society for Medical Oncology (ESMO) in Berlin schon wieder dem Ende entgegen. Zahlreiche Unternehmen haben bereits am Wochenende frische... ► Artikel lesen | |
NEUMORA THERAPEUTICS | 2,165 | +26,24 % | H.C. Wainwright maintains Buy rating on Neumora stock ahead of obesity drug data | ||
BEAM THERAPEUTICS | 27,935 | +0,96 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
ARCTURUS THERAPEUTICS | 11,700 | +0,86 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
ARVINAS | 9,080 | -2,47 % | ARVINAS, INC. - 8-K, Current Report | ||
NANOBIOTIX | 18,080 | -5,64 % | Nanobiotix S.A.: NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer | Treatment was well-tolerated and injection feasibility was confirmed in 13 patients with locally advanced adenocarcinoma of the esophagus85% (11/13) disease control rate (DCR)69% (9/13) objective... ► Artikel lesen |